In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
-
The changing pace of vaccines: How COVID-19 has impacted the future of infectious disease vaccine development
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development future vaccines
-
Business leaders call on corporate Ireland to support global vaccine rollout
In this article, CFO Brendan Brennan discusses the responsibility of CROs in the fight against COVID-19, particularly by helping the most vulnerable populations gain access to vaccines and treatments.
-
Morning Ireland business news
In this radio interview briefly discusses the disparity of vaccine rollouts of developed countries compared to less economically developed countries, and the role of ICON
-
Panel discussion: setting the roadmap for optimising cancer clinical trials
In this podcast, Martin Lachs discusses how clinical trials have been the backbone of cancer research.
-
The changing face of cell and gene therapy: impacts on planning and executing trials
In this webinar review some of the factors investigational teams should now consider in the planning and execution of cell and gene therapy development programs.
-
Contract research is having a moment right now. Will M&A splashes drive the industry to even greater heights?
ICON CEO, Dr. Steve Cutler offers his perspective of the ever-changing CRO landscape based on recent mergers and acquisitions in the industry.
-
Navigating the patient maze – pharma’s evolving challenge
Chris O'Toole considers the challenges that pharma companies may face when adopting a more patient-centric approach.
-
Irish clinical trials company ICON gets €4m state funding
This article reports on ICON’s multimillion-euro funding from the Irish government to enhance its decentralised and hybrid trial capabilities.
-
Irish clinical trials company ICON gets €4m State funding for R&D
ICON has received €4m in R&D investment from the Irish government to further develop its technology for decentralised and hybrid clinical trials.
